| Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer (NCT05067257) | Sorrento Therapeutics, Inc. | 2025-09-01 |
| Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer (NCT05361915) | Sorrento Therapeutics, Inc. | 2025-09-01 |
| Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise (NCT04992247) | Sorrento Therapeutics, Inc. | 2024-02-01 |
| An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis (NCT05692908) | Sorrento Therapeutics, Inc. | 2023-09-01 |
| Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors (NCT05361954) | Sorrento Therapeutics, Inc. | 2023-08-01 |
| Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents (NCT05372783) | Sorrento Therapeutics, Inc. | 2023-04-01 |
| A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies (NCT03999658) | Sorrento Therapeutics, Inc. | 2023-03-01 |
| Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma (NCT05308225) | Sorrento Therapeutics, Inc. | 2023-02-01 |
| Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors (NCT05060276) | Sorrento Therapeutics, Inc. | 2022-12-01 |
| Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. (NCT04118868) | Sorrento Therapeutics, Inc. | 2022-08-31 |
| Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers (NCT05364840) | Sorrento Therapeutics, Inc. | 2022-06-07 |
| Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (NCT04900519) | Sorrento Therapeutics, Inc. | 2021-11-24 |
| Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US) (NCT04906694) | Sorrento Therapeutics, Inc. | 2021-11-16 |
| Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress (NCT04905836) | Sorrento Therapeutics, Inc. | 2021-11-16 |
| Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress (NCT04903327) | Sorrento Therapeutics, Inc. | 2021-11-16 |
| Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis (NCT04885972) | Sorrento Therapeutics, Inc. | 2021-11-15 |
| Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection (NCT05074394) | Sorrento Therapeutics, Inc. | 2021-11-01 |
| Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases (NCT04037241) | Sorrento Therapeutics, Inc. | 2021-11-01 |
| Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome (NCT04909879) | Sorrento Therapeutics, Inc. | 2021-09-01 |
| Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise (NCT04909892) | Sorrento Therapeutics, Inc. | 2021-08-01 |
| Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK) (NCT04900428) | Sorrento Therapeutics, Inc. | 2021-07-16 |
| Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy (NCT05472649) | Sorrento Therapeutics, Inc. | 2021-06-16 |
| Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19 (NCT04771351) | Sorrento Therapeutics, Inc. | 2021-04-01 |
| Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis (NCT04316442) | Sorrento Therapeutics, Inc. | 2021-04-01 |
| Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms (NCT04734860) | Sorrento Therapeutics, Inc. | 2021-04-01 |
| Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed (NCT04386980) | Sorrento Therapeutics, Inc. | 2021-04-01 |
| Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19 (NCT04738175) | Sorrento Therapeutics, Inc. | 2021-04-01 |
| Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis (NCT04559412) | Sorrento Therapeutics, Inc. | 2021-03-15 |
| Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress (NCT04728698) | Sorrento Therapeutics, Inc. | 2021-03-01 |
| Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19 (NCT04528667) | Sorrento Therapeutics, Inc. | 2021-01-06 |
| Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19 (NCT04486001) | Sorrento Therapeutics, Inc. | 2020-12-15 |
| Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain (NCT04572776) | Sorrento Therapeutics, Inc. | 2020-12-01 |
| Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19 (NCT04584697) | Sorrento Therapeutics, Inc. | 2020-12-01 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee (NCT04044742) | Sorrento Therapeutics, Inc. | 2020-12-01 |
| Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19 (NCT04440007) | Sorrento Therapeutics, Inc. | 2020-10-09 |
| Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19 (NCT04454398) | Sorrento Therapeutics, Inc. | 2020-09-01 |
| Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases (NCT03818165) | Sorrento Therapeutics, Inc. | 2019-07-29 |
| Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients (NCT03464916) | Sorrento Therapeutics, Inc. | 2018-10-15 |
| CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) (NCT03682744) | Sorrento Therapeutics, Inc. | 2018-09-13 |
| Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis (NCT03542838) | Sorrento Therapeutics, Inc. | 2018-07-12 |
| Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002) (NCT03229798) | Sorrento Therapeutics, Inc. | 2018-01-17 |